Stentys has raised US$18 million
Stentys has raised US$18 million through private equity investment.
Stentys develops a new-generation stent designed for treatment of acute myocardial infarction and coronary artery bifurcations. Based in Princeton, New Jersey, and Paris, France, the company intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure.
Oaklins’ team in France advised Stentys on its two financing rounds, raising a total of US$18 million. The team continues to advise Stentys on corporate strategic matters.
Talk to the deal team
Related deals
Cerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn moreLargest AIM IPO in the business support services sector over the past five years has been completed
MHA plc raised US$131 million (£98 million) through a placing and retail offer, achieving a market capitalization of approximately US$363 million (£271 million) on admission. This was the largest AIM IPO in the business support services sector over the past five years. The IPO provides a platform for continued investment in technology, talent and acquisitions, supporting the group’s ambition to become a top 10 UK professional services firm.
Learn morePharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn more